Healthcare Congressional Oversight 2026
Congressional investigators are pre-positioning now - before November - and every healthcare organization with Medicare or Medicaid exposure is already in scope.
Congressional investigators are not waiting for November. They are already working.
In 2026, attorneys at Holland and Knight described what is happening inside the halls of the U.S. Congress: staffers are drafting investigative frameworks, cultivating external sources, and sending document preservation notices to healthcare companies. All of this - before a single vote has been cast in the 2026 midterm elections.
This is not a speculative risk. It is a present one. Healthcare has become the dominant domestic policy battleground of the decade, and the next congressional majority - whoever holds it - has already mapped the terrain. The organizations that treat oversight as a post-election problem are already behind.
This piece breaks down what investigators are targeting, why the scrutiny is bipartisan, what the Break Up Big Medicine Act means for vertically integrated health companies, and what specific steps healthcare leaders can take right now to assess their exposure.
1. The Pre-Election Playbook
Healthcare congressional oversight has traditionally followed a predictable cycle: a majority takes power, organizes its committees, and launches investigations six to twelve months into its term. What is different in 2026 is the timing.
According to attorneys at Holland and Knight's Washington, D.C. office, writing in Healthcare Dive in July 2026, congressional staffers are already building investigative infrastructure - including document preservation letters, external source networks, and investigative frameworks - months before the election.
This pre-positioning is deliberate and strategic. Running an investigation from zero is slow, visible, and resource-intensive. Building infrastructure before a majority is confirmed compresses the timeline dramatically. It means that the day after a new majority is seated, committee chairs can issue subpoenas instead of starting with organizational hearings.
There is a direct parallel to what happened in 2018 and 2022. When Democrats took the House in 2019, pharmaceutical pricing investigations launched in January. When Republicans took the House in 2023, UnitedHealth Group and PBMs were under scrutiny within weeks. Both parties have learned: investigations prepared in advance move faster, hit harder, and generate more political return than investigations built from scratch.
The 2026 version has one significant new element: bipartisan interest. Drug pricing, private equity in healthcare, hospital consolidation, and surprise billing are not partisan issues. They are political opportunities for both parties. That makes healthcare an unusually high-priority investigative target regardless of which party controls the next Congress.
2. The Eight Targets
The scope of expected investigations is broader than prior oversight cycles. Holland and Knight and Arnold and Porter have both published analyses identifying the following specific focus areas for the next Congress:
Drug pricing strategies and manufacturer price increases. This is the highest-priority item for both parties. The House Oversight Committee continued its multi-year probe of pharmaceutical pricing through Q1 2026. Senate Finance has ongoing investigations into insulin, GLP-1, and oncology drug pricing. Expect formal subpoenas and CEO testimony.
Insurance premium increases and cost-sharing structures. Following the January 2026 Ways and Means Committee hearing with major insurer CEOs, premium pricing and vertical integration with PBMs emerged as the dominant themes. Republicans focused on consolidation as a cost driver. Democrats focused on denial rates and prior authorization.
Facility fees and billing practices. Hospital facility fees have become a symbol of billing complexity. Patients who receive care at physician offices owned by health systems often receive separate facility fee charges they did not anticipate. This practice is legal but increasingly politically toxic, and it is explicitly named as an investigation target.
Compliance with the No Surprises Act. On May 28, 2026, CMS finalized new Independent Dispute Resolution rules (CMS-9897), the most significant IDR overhaul since the NSA's launch. Yet enforcement remains inconsistent. A 2024 study found that half of emergency physicians have seen insurers reprocess claims after an IDR win - increasing the patient's cost-sharing. Congressional investigators see this as a systemic compliance failure that falls squarely within oversight jurisdiction.
Medical debt collection and credit reporting practices. More than one-third of patients carry unpaid medical bills, and 71% of providers report collection timelines exceeding 30 days due to billing complexity. State action has accelerated: Oregon banned medical debt credit reporting as of January 2026. Maryland enacted near-total exclusions. Expect federal legislation and committee hearings to follow.
Private equity ownership structures. This is the area with the most bipartisan momentum and the most documented patient harm. A Grassley-Whitehouse Senate Budget Committee report found that PE-backed healthcare entities showed health and safety violations, chronic understaffing, and hospital closures at rates above industry averages.
Hospital acquisitions, closures, and real estate structures. When a PE firm acquires a hospital, it sometimes simultaneously sells the real estate to a Real Estate Investment Trust and leases it back, increasing fixed costs and limiting financial flexibility. Congress is examining whether these structures impair patient care and community health.
Staffing reductions following acquisitions. Multiple post-acquisition nursing home operators have faced investigations for cutting certified nursing assistant hours following PE acquisition. Connecticut enacted what may be the strictest PE nursing home transparency law in the country in 2026, requiring financial disclosures and banning PE from controlling day-to-day care decisions. Expect Congress to study this as a federal model.
3. The Private Equity Crosshairs
Of the eight investigation areas, private equity in healthcare has the deepest bipartisan roots and the most documented evidence of patient harm. This is not a political narrative - it is a research finding backed by a Senate investigation.
The Grassley-Whitehouse Senate Budget Committee report, released in a bipartisan inquiry, found that PE investment in healthcare was putting profits over patients and leading to health and safety violations, chronic understaffing, and hospital closures. That report created the evidentiary record that future investigations will draw on.
Private equity-backed Genesis HealthCare, one of the largest skilled nursing operators in the country, provided a concrete case study: nearly 200 residents at St. Joseph's Center in Connecticut were evacuated twice in 2026 - once for Legionella bacteria in the water system, and once for critical fire safety failures - highlighting what can happen when financial engineering overrides facility maintenance.
The policy response has already begun at the state level. Connecticut's 2026 law is the model: PE-owned nursing homes must now disclose all financial dealings with the state and are prohibited from controlling day-to-day care decisions. States including California, New York, and Illinois are advancing similar legislation.
For investors and operators, the political signal is clear: the era of PE-backed healthcare operating without structured transparency obligations is ending. Congressional investigations will accelerate that shift federally.
📊 Key stat: The Grassley-Whitehouse Senate report covered PE-backed entities showing health and safety violations at above-average rates. In 2026, states have passed or advanced PE healthcare transparency legislation in at least 8 states.
4. Drug Pricing and PBM Reform
The pharmaceutical and pharmacy benefit manager ecosystem represents the highest-risk zone for investigation, and the numbers explain why: three PBMs control 80% of U.S. prescription drug claims. Three drug wholesalers control 98% of all U.S. drug distribution. That concentration is the central political argument for structural action.
On February 10, 2026, Senators Josh Hawley (R-MO) and Elizabeth Warren (D-MA) introduced the Break Up Big Medicine Act - a bipartisan bill that would prohibit parent companies from simultaneously owning insurers, PBMs, pharmacies, physician practices, and drug wholesalers. The enforcement mechanism is aggressive: the FTC, HHS, DOJ, state attorneys general, and private parties can all bring lawsuits. Violators face profit disgorgement and forced asset sales within one year of enactment.
The practical targets of this legislation are UnitedHealth Group (which owns Optum, OptumRx, and thousands of physician practices), CVS Health (which owns Aetna, CVS Caremark, and CVS pharmacy), and Cigna (which owns Express Scripts and Evernorth). These three companies collectively employ hundreds of thousands of people and manage the financial architecture of care for over 200 million Americans.
Even without the Break Up Big Medicine Act passing, the Consolidated Appropriations Act signed on February 3, 2026 included landmark PBM reforms that will significantly reshape PBM operations across the commercial market and Medicare Part D beginning in 2028 to 2029. The direction of travel is clear, and investigators will use PBM market power as a forcing function for both legislation and oversight through the remainder of 2026.
5. No Surprises Act Compliance: Still a Live Problem
The No Surprises Act, signed in 2020 and implemented beginning in 2022, prohibits insurers from billing patients more than in-network cost-sharing for emergency care and certain out-of-network specialist services. Four years into implementation, compliance remains inconsistent and enforcement gaps are well documented.
A 2024 study of emergency physicians found that half had seen payers increase a patient's cost-sharing amount after the physician won an Independent Dispute Resolution (IDR) case. This is precisely the behavior the NSA was designed to prevent: when a provider wins at IDR, the insurer is supposed to pay the difference - not shift more cost to the patient. When insurers do the opposite, it defeats the law's purpose and creates congressional oversight exposure.
CMS acknowledged the problem with its May 28, 2026 final rule (CMS-9897), the most significant IDR procedural overhaul since the NSA's launch. The new rule tightens payer reprocessing requirements and strengthens enforcement mechanisms. But implementation requires monitoring, and Congress will likely hold hearings to assess whether the regulatory fix is working.
For health systems and insurers, the compliance implication is direct: if your IDR payer mix includes post-win reprocessing of patient cost-sharing, you are a specific audit target under the new rule and a likely witness in committee hearings.
Congressman Greg Murphy (R-NC) introduced the bipartisan No Surprises Enforcement Act to further strengthen enforcement, signaling that even Republicans see NSA enforcement as unfinished business.
Deep Dive: The ACCESS Framework
Holland and Knight proposed a five-question self-assessment for healthcare organizations evaluating their congressional investigation exposure. Understanding this framework helps organizations prioritize their pre-election preparation.
A - Affordability
Do your pricing, billing, or cost-sharing practices create visible patient harm? The test is not whether you are technically compliant. It is whether a congressional staffer reviewing your billing data could construct a narrative of visible harm. If your facility fees generate significant surprise bills, your drug pricing draws media coverage, or your prior authorization denial rates are above industry average, you are vulnerable.
C - Contracting
Do you have federal contracts or financial relationships with Trump administration political appointees? Congressional investigations often focus on the intersection of private financial interest and public decision-making. Companies with Medicare and Medicaid contracts are standard oversight targets. Companies with specific contracts signed by political appointees or with board-level ties to political figures face elevated scrutiny.
C - Consolidation
Have you acquired hospitals, practices, or facilities in the past three years? The antitrust and consolidation investigation thread is bipartisan and active. Arnold and Porter noted in July 2026 that health system acquisitions and closures are on the agenda for the next Congress. Organizations that have grown through acquisition - especially in markets where the acquisition reduced competition - should treat consolidation-related investigations as a baseline risk.
E - Equity Structure
Is private equity in your ownership chain, and how does it affect staffing? The Grassley-Whitehouse report and the state-level PE legislation create a clear evidentiary record. If your organization has PE ownership and your post-acquisition staffing metrics show reductions, you are in exactly the population that congressional investigators are building frameworks to examine.
S - Surprises
Are you in full, documented compliance with the No Surprises Act? Not just compliant in theory - but able to produce documentation that your IDR processes are operating as the statute requires, that you are not reprocessing patient cost-sharing after provider IDR wins, and that your facility fee disclosures meet current standards. If you cannot produce this documentation, you have work to do before November.
6. The Bipartisan Signal
One of the most important dynamics in the 2026 oversight environment is the unusual degree of bipartisan agreement on healthcare investigation targets. Drug pricing, PBM consolidation, private equity, and surprise billing have all attracted Republican and Democratic sponsors on major legislation.
This bipartisanship matters for risk assessment. In prior cycles, a change in majority often meant investigations were shelved and priorities reset. In 2026, the investigations that pre-positioned Democrats have built will largely align with the oversight agenda of a Republican majority as well - because the targets are the same.
The Warren-Hawley Break Up Big Medicine Act is the clearest signal. Elizabeth Warren is one of the most progressive voices in the Senate. Josh Hawley is one of its most conservative. They introduced structural separation legislation together. That alignment reflects years of accumulating evidence that the consolidation story is not partisan - it is a structural market failure that crosses ideological lines.
📊 Key stat: Three healthcare verticals - PBMs controlling 80% of Rx claims, three wholesalers controlling 98% of drug distribution, and MA plans collecting an estimated $76B annually in overpayments per MedPAC 2024 - represent the core investigation ecosystem regardless of which party takes the majority.
What This Means For You
The practical question for every healthcare organization is not whether congressional oversight is coming - it is when, from which angle, and whether you are prepared.
FQHC executives and community health center leaders: Your organizations are not the primary investigation targets, but you are often the downstream evidence in cases about coverage loss, billing abuse, and PE-driven closures. If you serve populations that have experienced surprise bills, medical debt, or coverage disruption from private equity consolidation in your market, you may be called as witnesses or asked to provide data. Document everything now.
Health system administrators and CMOs: Run the ACCESS framework. Specifically: audit your facility fee disclosure process, review your NSA compliance documentation, and if you have PE in your ownership chain, assess your post-acquisition staffing metrics against pre-acquisition baselines. The window for remediation is open now - it will narrow after November.
Radiologists and pulmonologists: AI-assisted diagnostic billing is explicitly named in the oversight framework. If you are billing under CPT 0721T, G0680, or other AI diagnostic codes, ensure your documentation supports the clinical indication and your payer contracts reflect the NSA's in-network requirements. Audit exposure before the next Congress seats.
Healthcare investors and founders: The Break Up Big Medicine Act is not law yet, but the due diligence implication is immediate. Any portfolio company that is vertically integrated across insurer, PBM, pharmacy, or provider lines needs a structural risk assessment. The enforcement mechanisms in the bill - including private rights of action and profit disgorgement - make this a material risk factor.
Policy advocates: The comment period on CMS-9897 (the IDR final rule) is the immediate action item. If your organization has documented NSA compliance failures - payers increasing cost-sharing after IDR wins, delayed payments, or incomplete disclosures - submitting comments with specific data creates a public record that congressional investigators will draw on.
Closing
The 2026 healthcare oversight cycle is structurally different from prior cycles in one important way: investigators are not waiting for the election results to start. They are pre-positioning. The investigation targets are defined. The frameworks are drafted. The subpoenas are ready to go.
This does not mean every healthcare organization faces congressional investigation. It means that organizations with exposure in drug pricing, PE ownership, insurance billing practices, PBM contracts, or NSA compliance should treat the pre-election period as their window for remediation - not their waiting room for risk.
The structural forces driving this moment - consolidation, market concentration, financial engineering in care delivery - are not going away regardless of which party controls the next Congress. Bipartisan legislation like Warren-Hawley, documented patient harm from PE ownership, and systemic NSA compliance failures have all crossed the threshold from political arguments to evidentiary records.
The question worth sitting with: if a congressional staffer reviewed your organization's billing data, acquisition history, and ownership structure today, what would they find?
About the Author
Jonathan Govette is the Co-Founder and CEO of Oatmeal Health, an AI lung cancer diagnostic company catching cancers earlier in the communities that need it most. Oatmeal uses AI to identify unscreened high-risk patients, navigate them to care, and score every lung CT for malignancy risk - billed under CPT 0721T. Stage I survival is 77%. Stage IV is 9%. We work in FQHCs because that gap is largest there.
Jonathan writes daily about radiology, pulmonology, AI diagnostics, health policy, hospital operations, and healthcare startups.
Subscribe to stay ahead of healthcare's most important shifts. Weekly deep-dives on AI, radiology, health policy, FQHCs, and the business of healthcare - written for operators, clinicians, and investors who want the signal, not the noise. Subscribe at oatmealhealthjonathangovette.substack.com
Key References
Healthcare Dive / Holland and Knight: "Healthcare faces congressional oversight heading into 2026 midterms and beyond" (July 2026) - primary source on pre-election investigative pre-positioning
Warren.senate.gov: "Warren, Hawley Introduce Bipartisan Bill to Break Up Big Medicine" (February 10, 2026) - Break Up Big Medicine Act details
Senate Budget Committee / Grassley-Whitehouse: "Private Equity in Health Care Shown to Harm Patients, Degrade Care and Drive Hospital Closures" - bipartisan Senate report on PE healthcare outcomes
McDermott+: "No Surprises Act implementation in 2026: The regulatory to-do list" - NSA enforcement gaps and CMS-9897 final rule analysis
Mintz: "Congress Passes Landmark PBM Reform in 2026 Spending Bill" (February 2026) - Consolidated Appropriations Act PBM reform provisions